Janssen Business Development

Identifying Pathways to Better Health
Through Collaboration
Janssen Business Development
About Us

Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.

Driving Collaborative Innovation to Accelerate Breakthroughs

The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s six defined therapeutic areas. We are very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, licenses, profit splits, and commercial partnerships.

The Janssen Business Development team has a proven, positive track record of deal performance. We are focused on genuine collaborations and take a thoughtful approach to risk-taking. No two deals are exactly alike, and we spend the time to understand the unique needs of our partners and optimize deal structures tailored to maximize value for all parties.

Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving, and we integrate deal makers with science leaders from the very beginning to optimize success.

If you represent the appropriate type of company, seek a collaboration or merger and acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.

Focus Areas

Our Pharmaceuticals business is focused in six core therapeutic areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. In addition, we have teams dedicated to Diagnostics & Enabling Technologies; Global Public Health; Emerging Markets; and Divestitures & Out-licensing. Janssen Business Development seeks opportunities across all of these areas where there is strong science and significant unmet patient need.

  •  
  •  
  •  
  •  
  •  
  •  
 
  •  
    Metabolism, Retinal Diseases, Thrombosis
    Cardiovascular and Metabolism
    Cardiovascular and Metabolism
  •  
    Gastroenterology, Rheumatology, Immuno Dermatology
    Immunology
    Immunology
  •  
    Viral Hepatitis & Adjacent Liver Diseases, Prevention & Treatment of Viral & Bacterial Respiratory Infections, Adjuvants, Novel Viral Vectors & Vaccine Technologies
    Infectious
    Diseases and Vaccines
    Infectious Diseases and Vaccines
  •  
    Mood Disorders, Neurodegenerative Disorders, Schizophrenia, Glutamatergic Pathway Diseases, Schizophrenia
    Neuroscience
    Neuroscience
  •  
    Prostate Cancer, Solid Tumor Targeted Therapy, Immuno-Oncology, Hematologic Malignancies
    Oncology
    Oncology
  •  
    Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
    Pulmonary Hypertension
    Pulmonary Hypertension
News
12/14/2018

Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension

12/03/2018

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

10/04/2018

Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection

07/18/2018

EUSA PHARMA ANNOUNCES ACQUISITION OF GLOBAL RIGHTS TO SYLVANT® (SILTUXIMAB) FROM JANSSEN SCIENCES IRELAND UC FOR $115 MILLION

06/11/2018

VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction

Leadership Team
Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

Johan Verbeeck, DVM, MsC
Johnson & Johnson Innovation,
Janssen Business Development
Email: jverbee2@ITS.JNJ.com
Telephone: +1 609-730-4532

contact